About Selecta Biosciences
Selecta Biosciences is a publicly listed company based in Watertown (United States) founded in 2008. Nanoparticle immunomodulatory drugs are developed for treating multiple diseases. Selecta Biosciences has raised $155.09 million across 20 funding rounds from investors including NIH, Gates Foundation and HHS. The company has 67 employees. Selecta Biosciences offers products and services including Descartes-08, Descartes-15, and Proprietary Platform. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Cartesian Therapeutics, Inc. Its competitors include Moderna, BridgeBio and BeiGene; 3 of its 3 listed competitors have raised funding.
Company details
Developer of nanoparticle immunomodulatory drugs for treating multiple diseases. The company develops targeted immunotherapies and vaccines that regulate immune responses to prevent and treat diseases. Its products include SEL-212 that is a non-immunogenic treatment for severe gout (Phase 2), SEL-403 a potent recombinant immunotoxin for targeting pancreatic cancer and mesothelioma (Phase 1), and 2 gene therapy candidates SEL-302 and SEL-313 for treating rare inborn errors of metabolism. The company has developed a tolerogenic Synthetic Vaccine Particles platform which it is planning to combine with a range of biologics for rare and serious diseases.
- Headquarters Watertown, United States
- Employees 67
- Stage Public
- SectorsHealthcare
- Website selectabio.com
- Social LinkedIn
- Legal Name Cartesian Therapeutics, Inc.
- Annual Revenue$85.08 M (USD)413as on Dec 31, 2021
- Net Profit-$25.69 M (USD)63as on Dec 31, 2021
- EBITDA-$4.6 M (USD)92as on Dec 31, 2021
- Total Equity Funding$155.09M (USD)
in 20 rounds
- Latest Funding Round$25M (USD), Post-IPO
Aug 2020
- InvestorsNIH
& 17 more
- Employee Count67
Products & Services of Selecta Biosciences
Selecta Biosciences offers a comprehensive portfolio of products and services, including Descartes-08, Descartes-15, and Proprietary Platform.
mRNA-based treatment targeting autoimmune diseases in clinical trials
Advanced mRNA therapy for autoimmune conditions through proprietary platform
Platform for creating mRNA cell therapies to address autoimmune disorders
Funding Insights of Selecta Biosciences
Selecta Biosciences has successfully raised a total of $155.09M across 20 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $155.09M
- Total Rounds 20
- Last Round Post-IPO — $25M
- First Round $2.5M
(May 2008)
- Investors Count 18
Latest 10 of 20 funding rounds of Selecta Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $25M | Post-IPO | – | – | – |
| Dec 2019 | $70M | Post-IPO | – | – | – |
| Sep 2019 | $5.75M | Post-IPO | – | – | – |
| Jul 2017 | $50M | Post-IPO | – | – | – |
| Dec 2016 | $5M | Post-IPO | – | – | – |
| Sep 2015 | $38M | Series C | – | Orbimed | |
| Sep 2015 | $100,399 | Grant | – | – | |
| Apr 2015 | $5.94M | Series C | – | – | – |
| Dec 2014 | $3.2M | Grant | – | – | |
| Oct 2014 | $20M | Series C | – | Polaris Partners, Orbimed | – |
18 investors in total: 17 institutional and 1 angel.
Investors in Selecta Biosciences
Selecta Biosciences has secured backing from 18 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include NIH, Gates Foundation and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Diversified investment, VC & financial advisory firm | 1974 | ajuib.co.kr | Seoul, South Korea | |
Life-Sciences focused Early stage Corporate VC Firm investing in the US | sanofiventures.com | Paris, France | ||
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
ROSNANO Group is engaged in nanotechnology and microelectronics development. | 2007 | rusnano.com | Moscow, Russia | |
Early-stage technology companies are funded by this venture capital firm. | i2bf.com | Beverly Hills, United States | ||
US focused VC firm | nanodimension.com | Woodside, United States | ||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
| spheraglobalhealthcare.com |
Investor details for Selecta Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Selecta Biosciences
46 people are tracked at Selecta Biosciences (18 in leadership, 18 in board & advisors, 10 in team); the tracked headcount is 67.
| Name | Role | Group |
|---|---|---|
Kelli Tea | Head Of Commercial | Leadership |
Emae Lee-Voritskul | Director Of Accounting | Leadership |
Cezary Karczewski | Director Of Quality Assurance | Leadership |
Miloš Miljković | Chief Medical Officer | Leadership |
Metin Kurtoglu | COO | Leadership |
Kirill Sergueev | Associate Director | Leadership |
Petr Ilyinskii | Vice President | Leadership |
Ross Denovellis | Associate Director, Financial Reporting And Technical Accounting | Leadership |
Renee Fedak | Director, Clinical Immunology | Leadership |
Christopher M. Jewell | Chief Scientific Officer | Leadership |
Hafsa Kamboh | Director, Translational Medicine | Leadership |
Emily English | Chief Operations Officer | Leadership |
Matt Duvernay | Director Of Research | Leadership |
Chris Jewell | Chief Scientific Officer | Leadership |
Carsten Brunn | President & CEO | Leadership |
Blaine Davis | Chief Financial Officer | Leadership |
C. Andrew Stewart | Senior Director Of Research | Leadership |
Yufei S. | Associate Director Of Discovery Research | Leadership |
Michael Benatar | Clinical Advisor | Board & advisors |
Tuan Vu | Clinical Advisor | Board & advisors |
26 more people are available in the full profile.
Complete people profiles for Selecta Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Selecta Biosciences
4 dated milestones of Selecta Biosciences across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Selecta Biosciences is founded.
- Funding First funding round of $2.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $25.0M.
Competitors of Selecta Biosciences
Selecta Biosciences has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed competitors of Selecta Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Selecta Biosciences
Websites that share an audience with Selecta Biosciences (selectabio.com).
Websites whose visitors overlap most with Selecta Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| senseonics.com | 100% | 15.2K | #1,883,577 | View details | |
| selecta.com | 33% | 91.3K | #364,395 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Selecta Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Selecta Biosciences
Complete news archive for Selecta Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Selecta Biosciences
Selecta Biosciences was founded in 2008.
Selecta Biosciences is headquartered in Watertown, United States.
Selecta Biosciences is a funded company, having raised a total of $155.09M across 20 funding rounds to date. The company's 1st funding round was a Series C of $20M, raised on May 2008.
Selecta Biosciences has 67 employees.
Annual revenue of Selecta Biosciences is $85.08M as on Dec 31, 2021.
Developer of nanoparticle immunomodulatory drugs for treating multiple diseases. The company develops targeted immunotherapies and vaccines that regulate immune responses to prevent and treat diseases. Its products include SEL-212 that is a non-immunogenic treatment for severe gout (Phase 2), SEL-403 a potent recombinant immunotoxin for targeting pancreatic cancer and mesothelioma (Phase 1), and 2 gene therapy candidates SEL-302 and SEL-313 for treating rare inborn errors of metabolism. The company has developed a tolerogenic Synthetic Vaccine Particles platform which it is planning to combine with a range of biologics for rare and serious diseases.
Selecta Biosciences offers Descartes-08, Descartes-15, and Proprietary Platform.
Selecta Biosciences has 18 investors. Key investors include NIH, Gates Foundation, HHS, Flagship Pioneering, and Orbimed.
Selecta Biosciences operates through Cartesian Therapeutics, Inc..